ORIC Pharmaceuticals advances its clinical pipeline with a new Phase 3 prostate cancer trial, balancing a robust cash runway against significant share dilution and a cautious market sentiment.
ORIC Pharmaceuticals has initiated the Himalayas-1 Phase 3 trial for its lead prostate cancer drug, rinzimetostat, supported by a $387.6 million cash position extending into 2028. While the company successfully secured a supply partnership with Bayer, it faces investor skepticism evidenced by a 16.83% short interest and a 40% increase in share dilution following recent capital raises.
The trial evaluates the efficacy of rinzimetostat in combination with darolutamide for prostate cancer, with radiographic progression-free survival as the primary endpoint.
Bayer is providing its drug NUBEQA at no cost to support ORIC's Phase 3 rinzimetostat trial, allowing for a combination therapy approach without ORIC relinquishing rights to its asset.